Originally published by our sister publication Infectious Disease Special Edition
Sanofi said it would ship nirsevimab (Beyfortus) starting in the beginning of the third quarter to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and runs through March.
The immunotherapy should begin in early fall, and these advance shipments will support the efforts of healthcare professionals in reaching this deadline.